Robert Werner Sells 7,000 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) CAO Robert Werner sold 7,000 shares of the stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $45.65, for a total value of $319,550.00. Following the sale, the chief accounting officer owned 58,738 shares of the company’s stock, valued at approximately $2,681,389.70. The trade was a 10.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Twist Bioscience Trading Up 4.5%

Shares of TWST stock opened at $49.23 on Friday. The company has a current ratio of 3.78, a quick ratio of 3.33 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $3.02 billion, a P/E ratio of -38.46 and a beta of 2.24. The firm’s fifty day simple moving average is $36.88 and its 200 day simple moving average is $32.04. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $54.26.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The company had revenue of $103.70 million for the quarter, compared to analyst estimates of $100.32 million. The firm’s quarterly revenue was up 16.9% compared to the same quarter last year. As a group, sell-side analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Quarry LP bought a new stake in shares of Twist Bioscience in the 3rd quarter valued at about $28,000. Smartleaf Asset Management LLC boosted its stake in shares of Twist Bioscience by 70.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after acquiring an additional 442 shares during the period. SBI Securities Co. Ltd. increased its holdings in shares of Twist Bioscience by 68.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after acquiring an additional 571 shares during the last quarter. National Bank of Canada FI bought a new stake in Twist Bioscience in the 3rd quarter valued at $46,000. Finally, Leonteq Securities AG bought a new stake in Twist Bioscience in the 4th quarter valued at $48,000.

Analysts Set New Price Targets

Several equities research analysts have recently commented on TWST shares. Stephens began coverage on shares of Twist Bioscience in a research note on Monday, November 3rd. They issued an “overweight” rating and a $41.00 target price on the stock. Robert W. Baird set a $50.00 price objective on Twist Bioscience in a report on Tuesday. Barclays raised their price target on Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a research report on Tuesday. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, December 29th. Seven analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience has an average rating of “Moderate Buy” and an average target price of $45.88.

Trending Headlines about Twist Bioscience

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Management raised guidance and commentary pointed to stronger demand from AI-related customers, suggesting improving end‑market traction (though reporters flagged execution risk). Twist Bioscience Guidance Lift Puts AI Demand And Risks In Focus
• Positive Sentiment: At least one analyst raised the price target sharply (20% boost to $48.35), signaling increased sell‑side bullishness that can support further upside and institutional interest. TWST price target increased by 20%
• Neutral Sentiment: Coverage pieces are reassessing valuation after the recent run‑up — useful for investors deciding whether the rally already embeds the guidance improvement or leaves room for more upside. Assessing Twist Bioscience Valuation
• Negative Sentiment: CEO Emily Leproust sold 5,001 shares at an average ~$46.58 (≈0.57% reduction); insider sales by the CEO can raise short‑term concern about insider conviction even if they are for diversification or routine tax/liquidity reasons. CEO sale filing
• Negative Sentiment: Other senior insiders sold this week (CAO Robert Werner sold 7,000 shares — a meaningful ~10.65% reduction in one filing — plus additional smaller sales; SVP Paula Green and insider Dennis Cho also sold). The cluster of senior‑level sales increases perceived insider pressure despite the positive guidance. CAO sale filing SVP sale filing Insider sale filing

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.